Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR Antibody + PD-1 Inhibitor + Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT06802835Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 1 year. Started Jul 2025; status: recruiting.
02
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06802835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06802835.